Article
Oncology
Zsolt Matula, Gabor Mikala, Szilvia Lukacsi, Janos Matko, Tamas Kovacs, Eva Monostori, Ferenc Uher, Istvan Valyi-Nagy
Summary: Mitochondrial transfer plays a crucial role in drug resistance acquisition in multiple myeloma, with bi-directional transfer occurring through tunneling nanotubes and partial cell fusion, especially under the influence of chemotherapeutic drugs. By influencing tumor metabolism and using oxidative phosphorylation inhibitors alongside chemotherapy, the supportive effect of stromal cells can be effectively avoided in myeloma cells.
Review
Cell Biology
Shamila D. Alipoor, Hong Chang
Summary: Multiple myeloma (MM) is a malignancy of plasma cells in the bone marrow characterized by the clonal proliferation of B-cells producing defective monoclonal immunoglobulins. Drug resistance remains a major challenge in MM therapy and is influenced by the crosstalk between MM cells and the bone marrow microenvironment (BME). Exosomal miRNAs play a crucial role in this communication, affecting the developmental trajectory and prognosis of MM.
Review
Cell Biology
Vanessa Innao, Vincenzo Rizzo, Andrea Gaetano Allegra, Caterina Musolino, Alessandro Allegra
Summary: Multiple myeloma cells acquire drug resistance through reprogramming their metabolic assessment via mitochondrial pathways. Some compounds, such as 2-methoxyestradiol and Artesunate, overcome resistance by increasing oxidative stress, while others restore efficacy through caspase-dependent tools. Each substance improves efficacy rates when used in combination with commonly used antimyeloma drugs.
Review
Oncology
Ali Tavakoli Pirzaman, Pouyan Ebrahimi, Amir Hossein Hasanpour, Mahdi Shakeri, Bahareh Babajani, Zahra Pourali Ganji, Hedye Babaei, Amirhossein Rahmati, Rezvan Hosseinzadeh, Shahrbanoo Doostmohamadian, Sohrab Kazemi
Summary: Multiple myeloma is a common type of cancer characterized by clonal plasma cells and aberrant monoclonal antibody accumulation. Researchers are currently studying the potential application of microRNAs (miRNAs) in the diagnosis, prognosis, and treatment of multiple myeloma.
TECHNOLOGY IN CANCER RESEARCH & TREATMENT
(2023)
Article
Oncology
Zemin Ren, Hildo Lantermans, Annemieke Kuil, Willem Kraan, Fernando Arenzana-Seisdedos, Marie Jose Kersten, Marcel Spaargaren, Steven T. Pals
Summary: Human bone marrow stromal cells express CXCL12 gamma and retain it on their cell surface through HSPGs, which controls adhesion of multiple myeloma cells to the stromal niche and mediates drug resistance.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2021)
Article
Oncology
Wenjiao Tang, Juan Xu, Caigang Xu
Summary: Multiple myeloma (MM) is a common but incurable hematological malignancy. The bone marrow microenvironment plays a crucial role in MM, and noncoding RNAs are emerging as important regulators of intercellular communication within the microenvironment. This review summarizes recent advances in the regulatory mechanisms of noncoding RNAs in MM and discusses their therapeutic potential.
Article
Biochemistry & Molecular Biology
Zsolt Matula, Ferenc Uher, Istvan Valyi-Nagy, Gabor Mikala
Summary: Belantamab mafodotin (belamaf) is an afucosylated monoclonal antibody that targets B cell maturation antigen (BCMA) and can eliminate myeloma cells through multiple mechanisms. However, primary myeloma cells can exhibit widely varying levels of BCMA expression, and low expression is associated with high resistance to belamaf. Additionally, we found that increasing concentrations of belamaf can lead to enhanced incorporation of mitochondria from bone marrow stromal cells, resulting in increased resistance to belamaf, similar to other medications like carfilzomib or venetoclax. The observed resistance to belamaf suggests the need for combination therapies to overcome the risk of antigen escape.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Biochemistry & Molecular Biology
Roberta Listro, Alessio Malacrida, Francesca Alessandra Ambrosio, Giacomo Rossino, Marcello Di Giacomo, Valeria Cavalloro, Martina Garbagnoli, Pasquale Linciano, Daniela Rossi, Guido Cavaletti, Giosue Costa, Stefano Alcaro, Mariarosaria Miloso, Simona Collina
Summary: The research team isolated a secondary metabolite called Hib-ester from Hibiscus Sabdariffa L. calyces, which possesses antiproliferative properties against human MM. Compound 13 and 14 were found to be more potent than Hib-ester, providing a new chemical class for developing possible drug candidates.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Biochemistry & Molecular Biology
Omar S. S. Al-Odat, Daniel A. A. Guirguis, Nicole K. K. Schmalbach, Gabriella Yao, Tulin Budak-Alpdogan, Subash C. C. Jonnalagadda, Manoj K. K. Pandey
Summary: In the past two decades, the understanding of multiple myeloma (MM) has significantly improved due to novel therapies targeting the MM in the bone marrow microenvironment. However, the mechanisms of resistance acquisition are still not well-known. The processes of autophagy and apoptosis play critical roles in MM cell growth, development, and survival. This review provides an overview of how autophagy and apoptosis are involved in MM progression and drug resistance, and suggests potential combination therapies targeting both pathways to improve outcomes in MM patients.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Biochemistry & Molecular Biology
Hamed Bashiri, Hossein Tabatabaeian
Summary: Multiple myeloma, the second most prevalent hematologic malignancy, has seen increased survival rates due to novel drugs and combination therapies. However, drug resistance remains a significant issue, with autophagic activity playing a critical role. High mobility group box protein 1 (HMGB1)-dependent autophagy and proteasome suppression-induced autophagy have been found to contribute to drug resistance in multiple myeloma.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Biochemistry & Molecular Biology
Srijit Das, Norsham Juliana, Noor Anisah Abu Yazit, Sahar Azmani, Izuddin Fahmy Abu
Summary: Multiple myeloma is a malignant hematological disease characterized by the abnormal proliferation of malignant plasma cells in the bone marrow. Genetic abnormalities, mutations, and translocation play a role in its pathophysiology. Early detection leads to a good prognosis, while distant metastasis indicates a poor outcome.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Pharmacology & Pharmacy
Omar Al-Odat, Max von Suskil, Robert Chitren, Weam Elbezanti, Sandeep Srivastava, Tulin Budak-Alpddogan, Subash Jonnalagadda, Bharat Aggarwal, Manoj Pandey
Summary: Mcl-1 protein plays a critical role in the progression of multiple myeloma and inhibiting this protein is considered a therapeutic strategy. Remarkable advancements have been made in the development of selective Mcl-1 inhibitors, which can be used as single agents or in combination therapy.
FRONTIERS IN PHARMACOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Max Von Suskil, Kazi Nasrin Sultana, Weam Othman Elbezanti, Omar S. Al-Odat, Robert Chitren, Amit K. Tiwari, Kishore B. Challagundla, Sandeep Kumar Srivastava, Subash C. Jonnalagadda, Tulin Budak-Alpdogan, Manoj K. Pandey
Summary: Multiple myeloma remains an incurable disease despite advancements in treatment, leading to aggressive relapses in patients. The cytosolic kinase BTK plays a crucial role in the survival of malignant clones and multiple myeloma stem cells, making it a promising therapeutic target. Inhibition of the BTK pathway may disrupt interactions between malignant clones and the bone marrow microenvironment in MM patients.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Cell Biology
Li Li, Shijun Yu, Jingde Chen, Ming Quan, Yong Gao, Yandong Li
Summary: This study identified the crucial roles of miR-15a, miR-20b, CDC37L1, and PPIA in regulating sorafenib resistance in hepatocellular carcinoma (HCC) cells. These factors may serve as therapeutic targets and predict the prognosis of patients treated with sorafenib.
CELL DEATH DISCOVERY
(2022)
Review
Chemistry, Medicinal
Guoyuan Tang, Shan Huang, Ji Luo, Yingmiao Wu, Shuai Zheng, Rongsheng Tong, Ling Zhong, Jianyou Shi
Summary: This review article summarizes the characteristics, clinical investigations, and future development directions of multiple myeloma drugs, including their structures, mechanisms of action, clinical study progress, and the potential applications of drugs that have not yet entered clinical trials.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
(2023)
